On October 28, 2019, RAMM Pharma Corp., formerly MTC Growth Fund-I Inc. (MTC), completed a business combination with Medic Plast S.A. and Yurelan S.A., and the related acquisition of RAMM Pharma Holdings Corp. (Finco) to form a vertically integrated business with medically registered and approved plant derived cannabinoid pharmaceutical products with a certified cannabis formulation facility and large scale hemp cultivation facility based in Uruguay.
Prior to the completion of the business combination, Finco completed a non-brokered private placement of unsecured convertible debentures for gross proceeds of $7 million and Finco and MTC completed non-brokered private placements resulting in the sale of an aggregate of 26,165,109 subscription receipts for aggregate gross proceeds of approximately $35.3 million. In connection with the completion of the business combination, the convertible debentures and subscription receipts were exchanged for common shares of RAMM Pharma Corp.
The common shares of RAMM Pharma Corp. will commence trading on the Canadian Securities Exchange on November 8, 2019 under the ticker symbol “RAMM”.
Cassels represented RAMM Pharma Corp. on this transaction with a deal team that included Jay Goldman, David Gardos and Florence Lau (Securities and Cannabis), Peter Sullivan, Carla Potter, Daniel Cipollone and Amanda Scolieri (Financial Services), and Chris Norton (Tax).